21 Dec |
(i) Licence agreement; and (ii) manufacturing and supply agreement entered into with Orient EuroPharma Co. Ltd. for the commercial launch of Fortacin™ in select territories in Asia, ex The People's Republic of China |
N/A |
03 Dec |
(i) Licence agreement; and (ii) manufacturing and supply agreement entered into with Wanbang Pharmaceutical Marketing and Distribution Co., Ltd. for the commercial launch of Fortacin™ in The People's Republic of China |
N/A |
19 Oct |
Successful registration of Fortacin™ in Hong Kong with the Hong Kong Department of Health - Drug Office |
N/A |
24 Aug |
2018 Interim Results Announcement |
N/A |
06 Jul |
Official registration of the Phase II validation study of Fortacin™ in respect of the Food and Drug Administration approval process in the United States |
N/A |
14 Jun |
2018 Annual General Meeting |
|
19 Apr |
Successful registration of Fortacin™ in Macau with the Macau Government - Health Bureau |
N/A |
23 Mar |
Receipt of a total of €4 million from Recordati during the period from 5 March 2018 to 23 March 2018 following the first commercial sale of Fortacin™ on schedule in each of Italy, France, Spain, Germany and Portugal |
N/A |
23 Mar |
2017 Annual Results Announcement |
N/A |
09 Feb |
Official launch, by way of first commercial sales from Recordati, to wholesalers in Italy, with first Fortacin™ sales expected to follow in France and Spain on 16 and 19 February 2018, respectively, and thereafter in Germany and Portugal on 1 March 2018 |
N/A |